Healthcare vs Non-Healthcare London, 5 August 2003 Opportunities in the European DAT Market © 2003 Frost & Sullivan. All rights reserved. This document contains highly confidential information and is the sole property of Frost & Sullivan. No part of it may be circulated, quoted, copied or otherwise reproduced without the written approval of Frost & Sullivan.

2 Agenda Introduction Agenda Market Trends DAT Uptake Test Matrices Role of the End-User Non-HC Market Evolution Emerging Companies Their Impact Take Home Messages Q & A

3 Market Trends National Strategies Rising Prison Population Methadone Monitoring Dearth of New End-Users Invasion of Privacy Lack of Legislation

4 A Frequently Heard Remark: “In terms of the adoption of drug testing, Europe is still five years behind the US...” UK DAT Product Manager, March 2003

5 High Low Medium DAT Uptake in Europe, 2002

6 Test Matrices & End-Users Blood Urine Hospital labs Remote hospital sites Primary care Prisons Police Workplace Blood Urine HCNon-HC Main samples taken Main demand sites

7 Non-HC Evolution Blood Urine Prisons Probation Police Workplace Oral fluid / saliva Sweat Hair TodayTomorrow

8 Ones to Watch Out For... Cozart Biosciences (RapiScan) Securetec (DrugWipe) OraSure Technologies / Drager Safety (Uplink)

9 Roadside Scenario Roadside Hospital Surgery Police station Urine sample Lab Blood sample Sweat POCT Saliva / oral fluid POCT Police

10 Take Home Messages HC market stable cf non-HC market growing Drug testing varies throughout Europe - but lags behind US Blood and urine most common samples New entrants starting to make waves

11 Thank You - Any Questions? Call us: +44 (0) Visit the web:

12 Special Offer! Both DAT reports: Euros Contact Account Manager: Maureen Ann Murphy Tel. +44 (0) or +49 (0) Fax. +44 (0) or +49 (0)